ALB and chronic kidney disease: The potential pharmacological targets relevant to CKD involve a reduction in the extent of proteinuria, serum creatinine levels, urinary albumin/creatinine ratio, and urea nitrogen levels, as well as a decrease in plasma albumin levels in CKD patients.